Open AccessHuman Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females
Author(s) -
Annika M. Hofstetter,
Danielle C. Ompad,
Melissa S. Stockwell,
Susan L. Rosenthal,
Karen Soren
Publication year - 2016
Publication title -
jama pediatrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.004
H-Index - 183
eISSN - 2168-6211
pISSN - 2168-6203
DOI - 10.1001/jamapediatrics.2015.3926
Subject(s) - medicine , vaccination , squamous intraepithelial lesion , cervical cancer , cervical intraepithelial neoplasia , population , cytology , gynecology , cervical screening , human papillomavirus , hpv infection , retrospective cohort study , obstetrics , cancer , immunology , pathology , environmental health
The quadrivalent human papillomavirus (HPV) vaccine was licensed for use in 9- through 26-year-old females in 2006. Postlicensure studies in Australia, Denmark, and Canada have demonstrated vaccine effectiveness against abnormal cervical cytology results. However, there are limited data describing postlicensure effectiveness in the United States, particularly among minority females at higher risk for HPV infection and cervical cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom